The Rapid Rise in Investment in Psychedelics— Cart Before the Horse Joshua PHELPS, Ravi N. SHAH, Jeffrey A. LIEBERMAN, JAMA Psychiatry, 2022, 79, (3), 189-190. Doi : 10.1001/jamapsychiatry.2021.3972 Anticipating a renaissance, many psychedelic medicine companies have conducted initial public offerings, where in private companies first issue news hares of stock for sale to the public, making the companies publicly traded entities.1 As of this writing, there are more than 50 publicly traded companies related to the development or administration of psychedelic like drugs in the US, with at least 3 valued at more than $1 billion. The market for psychedelic substances is projected to [...]
Lire la suitePsychedelic Medicines for Mood Disorders Current Evidence and Clinical Considerations Jerome Sarris; Diego Pinzon Rubiano; Kimberley Day; Nicole L. Galvão-Coelho; Daniel Perkins Current Opinion in Psychiatry, 2022, 35, (1), 22-29. doi : 10.1097/YCO.0000000000000759 https://www.medscape.com/viewarticle/964245 Abstract and Introduction Abstract Purpose of Review: Despite advances in treatment modalities for mood disorders over recent decades, further therapeutic options are still required. Increased research is occurring, with the pursuit of psychedelic-based pharmacotherapies for a range of mood disorders and other conditions. Recent Findings: Serotonergic psychedelics have been found to modulate brain networks underlying various psychiatric disorders, as well promoting neurogenesis and neuroplasticity. Randomized placebo-controlled trials have found psilocybin with psychological support effective at [...]
Lire la suiteAyahuasca : Uses, Phytochemical and Biological Activities, Edgar Antonio Estrella‑Parra et al., 2019
Ayahuasca : Uses, Phytochemical and Biological Activities Edgar Antonio Estrella‑Parra · Julio Cesar Almanza‑Pérez · Francisco Javier Alarcón‑Aguilar Natural Products and Bioprospecting, 2019, 9, 251–265 doi : 10.1007/s13659-019-0210-5 Abstract Ayahuasca (caapi, yajé), is a psychoactive brew from the Amazon Basin region of South America traditionally considered a “master plant.” It is prepared as a decoction from Banisteriopsis caapi and Psychotria viridis, which it is thought that it stimulates creative thinking and visual creativity. Native healers of the Orinoco and Amazon basins have used traditionally ayahuasca as a healing tool for multiple purposes, particularly to treat psychological disorders in the patients, with some beneficial effects experimentally [...]
Lire la suiteAntidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD) : a systematic review of clinical trials published in the last 25 years Rafael G. dos Santos, Flávia L. Osório, José Alexandre S. Crippa, Jordi Riba, Antônio W. Zuardi and Jaime E. C. Hallak Therapeutic Advances in Psychopharmacology, 2016, Vol. 6, (3) 193–213 Doi : 10.1177/2045125316638008 Abstract : To date, pharmacological treatments for mood and anxiety disorders and for drug dependence show limited efficacy, leaving a large number of patients suffering severe and persistent symptoms. Preliminary studies in animals and humans suggest that ayahuasca, psilocybin and lysergic acid diethylamide (LSD) may have [...]
Lire la suiteRecent Advances in the Neuropsychopharmacology of Serotonergic Hallucinogens Adam L. Halberstadt Behavioral Brain Research, 2015, 15, 277, 99–120. doi : 10.1016/j.bbr.2014.07.016 Abstract Serotonergic hallucinogens, such as (+)-lysergic acid diethylamide, psilocybin, and mescaline, are somewhat enigmatic substances. Although these drugs are derived from multiple chemical families, they all produce remarkably similar effects in animals and humans, and they show cross-tolerance. This article reviews the evidence demonstrating the serotonin 5-HT2A receptor is the primary site of hallucinogen action. The 5-HT2A receptor is responsible for mediating the effects of hallucinogens in human subjects, as well as in animal behavioral paradigms such as drug discrimination, head twitch response, prepulse [...]
Lire la suiteDe la première vague à la renaissance psychédélique ATHS 2019, Biarritz, 1-4 octobre 2019 Dr Bertrand LEBEAU LEIBOVICI Les psychédéliques « classiques » A l’exception du LSD, ce sont des substances naturelles consommées par certains peuples depuis des millénaires Les psychédéliques « classiques » interagissent avec le récepteur 5HT2a : LSD psilocybine DMT (Diméthyltryptamine) mescaline Une définition plus large des psychédéliques : Les entactogènes et empathogènes: MDMA, MDA, 2-CB, 2C-T-7 etc. Les substances dissociatives antagonistes NMDA : kétamine, PCP Les substances dissociatives agonistes kappa-opioïdes : ibogaïne et Salvia Divinorum Tryptamines et phényléthylamines : Les psychédéliques sont : soit des tryptamines : LSD, psilocybine, DMT, ibogaïne, bufoténine (5-hydroxy-DMT) soit des phényléthylamines: MDMA, mescaline, MDA, 2C-B etc. La psychiatrie en [...]
Lire la suiteReported effects of psychedelic use on those with low well-being given various emotional states and social contexts Natasha L. Mason, Patrick C. Dolder and Kim P.C. Kuypers Drug Science, Policy and Law, 2020, Volume 6, 1–11. Doi : 10.1177/2050324519900068 Abstract Background : It has been suggested that the outcome of the psychedelic experience is dependent on set and setting. While scientific research into the therapeutic potential of psychedelics is growing, it is clear that in clinical populations an optimal set and setting will not always be attainable. It was aimed to assess under which emotional and environmental circumstances psychedelic users use psychedelics, and the outcome [...]
Lire la suiteTherapeutic Potential of Psychedelic Drugs Justin Briglio University of Maine, 2015, 31 p. Table of Contents Introduction......................................................................................................................................3 History of Psychedelic Research.....................................................................................................6 Recent Research...............................................................................................................................8 Neurobiology of Psychedelics.........................................................................................................9 Therapeutic Potential of Psilocybin...............................................................................................12 Therapeutic Potential of LSD........................................................................................................15 Therapeutic Potential of Ayahuasca..............................................................................................19 Therapeutic Potential of Ibogaine..................................................................................................22 Conclusion.....................................................................................................................................26 References......................................................................................................................................28 A psychedelic compound is a psychoactive drug whose main action is to alter perception and cognition. Psychedelics are distinctive from other psychoactive drugs in that they alter the mind, whereas opiates or stimulants alter the mood (Meyer & Quenzer, 2013). Psychedelics affect nature of consciousness itself and access otherwise unknown states of consciousness, as opposed to affecting the degree or extent of one's consciousness and inducing proverbial moods such as [...]
Lire la suiteL’invité de 6h20 – La médecine psychédélique renaît peu à peu Fév15 Revue de presse vendredi 14 février 2020 par Mathilde Munos Stéphanie Chayet, journaliste, auteure de Phantastica, ces substances interdites qui guérissent (Grasset) Stéphanie Chayet : “Il n’y a pas plus de troubles psychiatriques chez les usagers de drogues psychédéliques Après le cannabis thérapeutique, verra-t-on d’autres substances, aujourd’hui considérées comme des drogues, devenir des médicaments ? , nous en parlons avec la journaliste Stéphanie Chayet, auteure de « Phantastica ». Elle est l’invitée du 5/7. https://www.circ-asso.net/linvite-de-6h20-la-medecine-psychedelique-renait-peu-a-peu/ Lecteur audio 00:00 00:00 Source : franceinter.fr Catégorie Revue de presse 15 février 2020
Lire la suiteAyahuasca : l’importance du cadre et de l’intention lors de prise de psychédéliques Jean-Charles Bernard Psychotropes, 2016, 2, Vol. 22, pages 81 à 100 ISSN 1245-2092, ISBN 9782807390485 Résumé : La boisson amazonienne ayahuasca génère de profonds états modifiés de conscience et s’ingère “traditionnellement” lors de rituels dans un but précis : apprentissage, guérison, divination… Le sens de l’expérience est consubstantiel au rituel dans la culture chamanique où l’accès au “monde-autre” appartient au champ des possibles. La globalisation de cette boisson a vu naître de nouveaux usages, tout d’abord dans les religions de l’ayahuasca au Brésil et dans les centres néo-psychothérapiques en Amérique du [...]
Lire la suite